Table 1:

Known liver CSC markers and their role in cellular metabolism

Marker	Metabolic phenotype	Function in therapy	Reference
CD13	Maintain lower levels of mitochondrial ROS	Combining a CD13 inhibitor with a chemo/radiation therapy inhibit tumor progression	27,38
CD133	Decrease mitochondrial OXPHOS and promotes glycolysis	Targeting glycolytic enzymes represses stemness properties in CD133+ PLC cells	32,72
CD90	Higher levels of the mitochondrial ROS	Actively proliferate and are sensitive to 5-FU therapy	27
CD44	Maintaining low ROS levels through promoting glutathione synthesis	Combining a CD44 inhibitor with a Sulfasalazine inhibit tumor progression	74
EPCAM	Maintaining low ROS levels	Not reported in this paper	16
CD24	Not reported	Not reported
DLK1	Not reported	Not reported
OV6	Not reported	Not reported